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The opportunistic gram-positive pathogen Staphylo-
coccus aureus is a leading cause of pneumonia
and sepsis. Staphylococcal a-toxin, a prototypical
pore-forming toxin, is a major virulence factor of
S. aureus clinical isolates, and lung epithelial cells
are highly sensitive to a-toxin’s cytolytic activity.
Type I interferon (IFN) signaling activated in response
to S. aureus increases pulmonary cell resistance to
a-toxin, but the underlying mechanisms are unchar-
acterized. We show that IFNa protects human lung
epithelial cells from a-toxin-induced intracellular
ATP depletion and cell death by reducing extracel-
lular ATP leakage. This effect depends on protein
palmitoylation and induction of phospholipid scram-
blase 1 (PLSCR1). IFNa-induced PLSCR1 associates
with the cytoskeleton after exposure to a-toxin, and
cellular depletion of PLSCR1 negates IFN-induced
protection from a-toxin. PLSCR1-deficient mice
display enhanced sensitivity to inhaled a-toxin and
an a-toxin-producing S. aureus strain. These results
uncover PLSCR1 activity as part of an innate protec-
tive mechanism to a bacterial pore-forming toxin.
INTRODUCTION
Staphylococcus aureus is an opportunistic gram-positive path-
ogen and the leading cause of severe and life-threatening infec-
tions, including pneumonia and sepsis (Kallen et al., 2010;
Schreiber et al., 2011). Many clinical isolates of S. aureus
produce a-toxin, a prototypical pore-forming toxin and a major
virulence factor (Bartlett et al., 2008; Menzies and Kernodle,
1996; O’Reilly et al., 1986; Wilke and Bubeck Wardenburg,
2010). Human epithelial cells express ADAM10, a high-affinity
protein receptor for a-toxin, which makes them intrinsically
sensitive to the cytotoxic effects of a-toxin (Wilke and Bubeck
Wardenburg, 2010). Formation of a-toxin pores in the plasma
membrane of sensitive cells leads to major changes in the
gradients of ions across the membrane, depletion of intracellular
ATP, activation of pro-nflammatory cascades, and ultimate
cell death (Bhakdi and Tranum-Jensen, 1991; Craven et al.,
2009; Pre´vost et al., 2001; Ratner et al., 2006; Rose et al.,70 Cell Host & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier I2002). Excessive inflammation and death of respiratory epithelial
cells triggered by a-toxin during pneumonia contribute to acute
lung injury and worsen the outcome of infection (Bartlett et al.,
2008; Bubeck Wardenburg and Schneewind, 2008; Rose et al.,
2002). Neutralization of the cytolytic activity of a-toxin protects
animals from S. aureus (Bubeck Wardenburg and Schneewind,
2008; Kennedy et al., 2010; McCormick et al., 2009; Menzies
and Kernodle, 1996; Ragle and Bubeck Wardenburg, 2009),
suggesting that a-toxin is a promising target for intervention
during staphylococcal infections.
Cellular defense against a-toxin and other pore-forming toxins
relies on constriction of the a-toxin pores (Valeva et al., 2000),
activation of mitogen-activated protein kinases (Husmann
et al., 2006), induction of lipogenic genes via activation of sterol
response element binding proteins (SREBPs) by caspase-1
(Gurcel et al., 2006), and accelerated endocytosis and exocy-
tosis (Husmann et al., 2009; Idone et al., 2008). Further charac-
terization of host-intrinsic mechanisms of resistance to a-toxin
should facilitate development of new therapeutic approaches
for staphylococcal infection.
We have previously reported that type I interferons (IFNs)
increase cell resistance to a-toxin, presumably via induction of
interferon-regulated genes involved in lipidmetabolism (Yarovin-
sky et al., 2008). However, activation of type I IFN signaling by
staphylococcal protein A increased inflammation in the lungs
(Martin et al., 2009). These opposing effects of I IFNs may be
exerted through transcriptional regulation of distinct subsets of
IFN-regulated genes. Therefore, it is important to identify which
IFN-regulated genes and pathways are necessary for protection
from a-toxin.
In this study, we focused on human lung epithelial cells since
they are highly sensitive to a-toxin and represent the first line of
defense against S. aureus during respiratory infections. We
demonstrated that IFNa protects human lung epithelial cells
from a-toxin-induced cell death by reducing release of cellular
ATP into extracellular space. Using an ATP-based cell viability
screening assay and bioinformatics analyses, we found that
IFNa-induced protection from a-toxin is dependent on protein
palmitoylation and induction of phospholipid scramblase 1
(PLSCR1). Increased expression of PLSCR1 has been previously
implicated in bidirectional translocation of membrane phospho-
lipids across plasma membrane and amplification of transcrip-
tional responses to type I IFNs (Dong et al., 2004; Stout et al.,
1997; Zhou et al., 2000). Here, we show that IFNa-induced
protection from a-toxin correlates with accumulation of PLSCR1
in the cytoskeleton-associated protein fractions.nc.
Figure 1. IFNa Protects Lung Epithelial Cells from a-Toxin-Induced Cell Death and Depletion of Intracellular ATP
Human primary SAECs were pretreated with medium or IFNa (1000 U/ml) for 24 hr and treated with a-toxin (0.1 mg/ml) for additional 24 hr.
(A) Representative photomicrographs of cells stained with calcein AM (green, live) and EthD-1 (red, dead). The scale bar represents 100 mm.
(B) Percent dead cells (mean ± SD of five independent experiments, each carried out in quadruplicate wells).
(C) Relative levels of intracellular ATP (perecent remaining, relative to untreated cells at each time point) weremeasured in SAECs at the indicated time points after
a-toxin (mean ± SD of quadruplicate wells; the data are representative of five experiments).
(D) Relative ATP levels in IFNa-pretreated A549 cells at 6 hr after a-toxin (mean ± SD of five independent experiments, each carried out in quadruplicate wells).
(E and F) Relative ATP levels in medium- or IFNa-pretreated A549 cells after incubation with conditioned medium (diluted 1:100) from cultures of Hla+ or Hla–
S. aureus. The data (mean ± SD of quadruplicate wells) are representative of three independent experiments.
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IFNa Reduces a-Toxin-Induced Cell Death and Release
of Extracellular ATP
Exposure of human primary small airway epithelial cells (SAECs)
to staphylococcal a-toxin for 24 hr resulted in significant cell
death, which was preceded by rapid depletion of intracellular
ATP (Figure 1). Pretreatment of SAECs with IFNa for 24 hr signif-
icantly inhibited depletion of ATP and reduced cell death trig-
gered by a-toxin. Although higher concentrations of a-toxin
(0.5–2.5 mg/ml) were required to trigger ATP depletion in A549
cells, it was similarly inhibited by IFNa pretreatment (Figure 1D).Cell HPretreatment with IFNa also inhibited ATP depletion from
A549 cells incubated with conditioned medium from a-toxin-
producing strain of S. aureus (Figures 1E and 1F). These data
indicate that type I IFNs protect lung epithelial cells from the
cytotoxic effects of a-toxin.
To determine how IFNa protects cells from a-toxin, we
evaluated the early events after exposure to a-toxin. IFNa
pretreatment did not decrease oligomerization of a-toxin, activa-
tion of p38 mitogen-activated protein (MAP) kinase, and efflux of
potassium (Figure S1 available online). Within the first 30 min
of a-toxin exposure, association of a-toxin with ADAM10
or recently reported a-toxin-induced ADAM10-dependentost & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier Inc. 71
Figure 2. Exposure to a-Toxin Triggers Release of eATP that Is In-
hibited by IFNa Pretreatment
(A and B) A549 cells were treated with the indicated concentrations of a-toxin
(A) or diluted conditioned medium from cultures of Hla+ or Hla– S. aureus (B).
The curves show normalized mean luminescence intensity kinetics measured
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by IFNa pretreatment, albeit they were slightly reduced at 2 hr
(Figure S1). To evaluate whether a-toxin triggers release of
ATP into extracellular space, we treated A549 cells with a-toxin
in the presence of luciferin and luciferase in the medium. After
a short lag period, a-toxin triggered a robust increase in ATP-
dependent luminescence peaking between 20 and 40 min with
maximal luminescence intensity observed at 2.5 mg/ml of a-toxin
(Figure 2A). Althoughmany bacterial products such as endotoxin
and staphylococcal peptidoglycan may trigger extracellular
ATP (eATP) release (De Vuyst et al., 2007; Robertson et al.,
2010), we found that a-toxin was a necessary and sufficient
secreted factor of S. aureus for eATP release from lung epithelial
cells: incubation of A549 cells with conditioned medium from
a-toxin-producing Hla+ strain of S. aureus triggered rapid and
robust eATP release, which was virtually nondetectable after
incubation with conditioned medium from isogenic Hla– a-toxin
mutant strain (Figure 2B). Thus, exposure of lung epithelial cells
to a-toxin leads to eATP release.
We also measured eATP in the conditioned medium collected
from cells at 15 min intervals after exposure to a-toxin, which al-
lowed us to avoid luciferase inactivation by prolonged incubation
at 37C (Seminario-Vidal et al., 2009). The baseline eATP levels
released by A549 cells within 1 hr of culture under those condi-
tions were below 20 nM and not affected by IFNa treatment.
The concentrations of eATP peaked at 30 min after a-toxin and
reached 1805 ± 248 nM eATP. IFNa pretreatment did not change
the kinetics of eATP release after a-toxin treatment but signifi-
cantly reduced peak eATP concentrations to 1341 ± 170 nM
(p < 0.01; the data are mean ± SEM of seven independent exper-
iments each performed in quadruplicate cultures). Treatment of
human primary SAECs with a-toxin also triggered eATP release,
albeit peak eATP concentrations were much lower than in A549
cells (Figure 2C). Importantly, IFNa pretreatment of SAEC signif-
icantly decreased eATP levels after a-toxin exposure.
The reduction in a-toxin-induced eATP concentrations in
IFNa-pretreated cells could not be explained by changes inevery minute within 1 hr after a-toxin. Data in (A) are mean of quadruplicate
cultures and are representative of two independent experiments. Data in (B)
are mean ± SEM of triplicate cultures and are representative of three inde-
pendent experiments.
(C) SAECs were pretreated with IFNa for 24 hr and exposed to 0.1 mg/ml
a-toxin for 30 min. Cell-free conditioned medium was used to measure eATP.
The data are mean ± SD of quadruplicate cultures and are representative of
three independent experiments.
(D) Exogenous ATP was added to medium- or IFNa-pretreated A549 cells for
30 min. Cell-free conditioned medium was used to measure remaining ATP
(percent input, the data are mean ± SD of quadruplicate cultures and are
representative of three experiments).
(E) A549 cells were pretreated with oxidized ATP for 2 hr prior to exposure to
2.5 mg/ml a-toxin. Cell death at 24 hr after a-toxin is shown. The data are
mean ± SD of quadruplicate cultures and are representative of three inde-
pendent experiments.
(F) C57BL6/ mice (8 weeks old, females) were administered a-toxin or
a-toxin with oxidized ATP diluted in 50 ml sterile PBS via intranasal route.
Body temperature was measured at the indicated time points. The data are
mean ± SD, n = 5. Control mice received 50 ml sterile PBS. Asterisks indicate
the time points when the body temperature in mice treated with a-toxin alone
was significantly lower than in other groups of mice (p < 0.05).
See also Figure S1.
nc.
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exogenous ATP, the remaining ATP levels were similar between
medium- and IFNa-pretreated cells. IFNa pretreatment actually
slowed degradation of exogenously added ATP at 1000 nM
concentration range (Figure 2D).
Extracellular nucleotides may contribute to cell lysis by
bacterial pore-forming toxins through autocrine or paracrine
activation of P2 receptors (Skals et al., 2009). We found that
pretreatment of A549 cells with 500–1000 mM of oxidized ATP
(a nonselective antagonist of P2 receptors) significantly inhibited
a-toxin-induced cell death (Figure 2E). Moreover, oxidized
ATP protected mice from hypothermia induced by intranasal
administration of sublethal doses of a-toxin (Figure 2F). These
data suggest that a-toxin-induced release of eATP and, probably
other nucleotides, contribute to the cytotoxic effects of a-toxin
via P2 receptors.
Identification of PLSCR1 as a Candidate Gene Involved
in IFNa-Induced Protection from a-Toxin
To characterize signaling pathways involved in IFNa-induced
protection from a-toxin, we carried out a screening assay in
A549 cells treated with IFNa, chemical inhibitors and a-toxin as
depicted in Figure S2. By measuring remaining intracellular
ATP after a-toxin treatment as the readout, we found that
IFNa-induced protection from a-toxin was not affected by inhib-
itors of caspase-1 (Ac-YVAD-FMK, 10 mM), sterol response
element binding proteins (25-OH-cholesterol, 50 mM), ERK
MAP kinase (UO126, 10 mM), and EGFR tyrosine kinase
(AG1478, 15 mM) (Figure S2). Inhibitors of caspases (zVAD-
FMK as a pan-caspase inhibitor, 10 mM), gene transcription
(actinomycin D, 2.5 mg/ml), protein synthesis (cycloheximide,
50 mg/ml), and removal of serum (i.e., treatment of cells in
serum-free medium) showed moderate, but statistically sig-
nificant, protection of both medium- and IFNa-pretreated cells
from a-toxin. However, inhibitors of p38-MAP kinase
(SB203580, 10 mM), PI3 kinase (LY294002, 10 mM), and fatty
acid synthase (cerulenin, 10 mg/ml) significantly affected the
protective effect of IFNa (Figure S2). Furthermore, inhibition of
protein palmitoylation with 2-bromopalmitate (100 mM) effec-
tively wiped out IFNa-induced protection from a-toxin (Fig-
ure 3A). The effects of 2-bromopalmitate were also evident
when it was added to the cells 30 min after IFNa, i.e., approxi-
mately 24 hr prior to a-toxin (Figure 3B). This treatment also
sensitized A549 cells to a-toxin-induced cell death (Figure 3C),
providing additional evidence for involvement of protein palmi-
toylation in protection of lung epithelial cells from a-toxin.
Using palmitoylation and regulation by type I IFNs as selection
criteria, we analyzed the overlap between the 227 human genes
associated with protein palmitoylation (Yang et al., 2010) and
218 IFN-regulated genes expressed in A549 cells (Sanda et al.,
2006) and identified FAS (tumor necrosis factor receptor super-
family, member 6) and PLSCR1 (Figure 3D). We dismissed FAS
since interferons increase its expression, which is more likely
to sensitize cells to FasL-mediated cell death than protect
them from a-toxin (Chawla-Sarkar et al., 2003). Therefore, we
focused our further analyses on PLSCR1 since it is induced by
type I IFNs (Zhou et al., 2000), palmitoylation of PLSCR1 protein
directs it to lipid rafts in plasma membrane (Wiedmer et al.,
2003), where a-toxin preferentially binds (Valeva et al., 2006;Cell HWilke and Bubeck Wardenburg, 2010), and PLSCR1 is abun-
dantly expressed by macrophages and neutrophils (Chen
et al., 2011; Zhou et al., 2002), which are highly resistant to
a-toxin-induced cell death (Valeva et al., 1997).
To determine whether PLSCR1 is induced in lung epithelial
cells, we analyzed PLSCR1 expression in medium- and IFNa-
pretreated human primary SAECs and A549 cells. At the base-
line, PLSCR1 was hardly detectable; however, IFNa treatment
led to robust induction of PLSCR1 protein (Figure 3E). PLSCR1
localized primarily in a perinuclear region, albeit some nuclear
and membrane staining was also evident. Remarkably, after
incubation of IFNa-pretreated cells with a-toxin for 2 hr, most
of the endocytosed a-toxin colocalized with a fraction of
PLSCR1 (Figure 3F). Thus, IFNa-induced PLSCR1 may be in
proximity with a-toxin.
PLSCR1 Is Necessary for IFNa-Induced Protection
from a-Toxin
To examine the role of PLSCR1 in IFNa-induced protection from
a-toxin, we suppressed its induction by transfecting cells with
PLSCR1-specific short hairpin RNA (shRNA). A nonsilencing
(NS) control shRNA had no effect on PLSCR1 expression,
whereas PLSCR1-specific shRNA further decreased the base-
line and prevented IFNa-induced expression of PLSCR1 (Figures
4A and 4B). Furthermore, PLSCR1-specific shRNA did not affect
baseline and IFNa-induced expression of STAT1 (Figures 4A and
4C). NS shRNA had no effect on a-toxin-induced ATP depletion
in medium- or IFNa-pretreated A549 cells to a-toxin (Figure 4D).
However, PLSCR1-specific shRNA negated the protective
effects of IFNa on a-toxin-induced depletion of ATP (Figure 4D).
Furthermore, PLSCR1-specific shRNA attenuated IFNa-induced
protection from a-toxin-induced cell death (Figure 4E and Fig-
ure S3). These data suggest that induction of PLSCR1 is neces-
sary for IFNa-induced protection from a-toxin.
To explore the role of PLSCR1 in responses to a-toxin in vivo,
we treated PLSCR1 knockout (PLSCR1/) mice and littermate
heterozygous (PLSCR1+/) mice (Zhou et al., 2002) with a-toxin
via intranasal route. PLSCR1 deficiency (Figure 4F) had no effect
on the early a-toxin-induced hypothermia but resulted in
impaired recovery of body temperature (Figure 4G), suggesting
that lack of PLSCR1 increases sensitivity of mice to inhaled
a-toxin. Subsequently, we tested whether PLSCR1 deficiency
alters the outcome of experimental staphylococcal pneumonia
due to infection with a-toxin-producing Hla+ strain of S. aureus
or isogenic a-toxinmutantHla– strain ofS. aureus. When infected
with 2.5 3 108 CFU of Hla+ S. aureus, a larger fraction of
PLSCR1/ mice developed moribund condition sooner than
PLSCR1+/ littermates (Figure 4H). Infection with Hla+ resulted
in severe hypothermia at 6 hr postinfection (p.i.) in PLSCR1+/
and PLSCR1/ mice (Figure 4I). Among the survivors at 16 hr
p.i., three PLSCR1/ mice and seven PLSCR+/ mice started
recovering their body temperature. These mice eventually
survived the infection with Hla+ S. aureus. Transient and less
severe hypothermia was observed in PLSCR1+/ and
PLSCR1/ mice infected with the Hla– strain (3.65 3 108 CFU/
mouse). Importantly, all mice recovered their body temperature
by 16 hr and none of the mice were moribund within 72 hr p.i.
with Hla– S. aureus. These data indicate that PLSCR1 deficiency
increases sensitivity of mice to live a-toxin-producing S. aureus.ost & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier Inc. 73
Figure 3. Identification of PLSCR1 as a Candidate Gene Involved in IFNa-Induced Protection from a-Toxin
(A and B) Medium- or IFNa-pretreated A549 cells were incubated with 2-bromopalmitate 30 min prior to a-toxin (A) or 30 min after IFNa (i.e., approximately 24 hr
prior to a-toxin) (B). Relative ATP levels remaining after 16 hr treatment with a-toxin are shown in (A) and (B) (mean ± SD of quadruplicate cultures normalized
to ATP levels in A549 cells pretreated with medium and DMSO without a-toxin).
(C) Cell death measured by staining with 7-amino-actinomycin D and flow cytometry after 24 hr treatment with a-toxin. The data are mean ± SD of triplicate
cultures. Asterisks indicate statistically significant interaction between 2-bromopalmitate and IFNa pretreatment at the indicated concentration of a-toxin
(p < 0.005).
(D) Venn diagram showing the overlap between IFN-regulated genes expressed in A549 cells and genes associated with protein palmitoylation.
(E) SAEC and A549 cells were treated with 1000 U/ml IFNa for 24 hr and analyzed for expression of PLSCR1 by immunofluorescence.
(F) Medium and IFNa-pretreated A549 cells were exposed to 2.5 mg/ml of a-toxin at 37C for 30 min or 2 hr, washed twice, fixed, permeabilized, and stained
withmouse anti-human PLSCR1 and rabbit anti-a-toxin antibodies followed by secondary antibodies (goat anti-mouse conjugatedwith Alexa Fluor-488 and goat
anti-rabbit conjugated with Alexa Fluor-647).
Representative photomicrographs from three independent experiments are shown. Scale bars represent 20 mm. See also Figure S2.
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Figure 4. Expression of PLSCR1 Is Necessary for IFNa-Induced Protection from a-Toxin
(A–C) A549 cells were stably transfected with PLSCR1-specific or nonsilencing (NS) shRNA vectors and analyzed for expression of PLSCR1 and STAT1 by
immunoblotting. A representative immunoblot (A) and densitometry analyses of PLSCR1 (B) and STAT1 (C) expression normalized to actin are shown (mean ± SD
of three independent experiments). A549 cells stably expressing PLSCR1-specific or NS shRNA were pretreated with IFNa and treated with 2.5 mg/ml a-toxin.
(D) Relative ATP levels remaining after 16 hr treatment with a-toxin. The data are mean ± SD of three independent experiments.
(E) Cell death after 24 hr treatment with a-toxin. The data are mean ± SD of quadruplicate cultures and are representative of three experiments.
(F) Immunoblot analysis of PLSCR1 expression in the lungs of littermate PLSCR1+/ and PLSCR1/ mice.
(G) Littermate PLSCR1/ and PLSCR1+/ mice were administered a-toxin via intranasal route. Body temperature was measured at the indicated time points.
Asterisk indicates statistically significant difference in body temperature between the groups at 24 hr after a-toxin (mean ± SEM, p < 0.05, n = 4).
(H) Littermate PLSCR1/ and PLSCR1+/ mice were infected with 2.5 3 108 CFU/mouse of a-toxin-producing Hla+ S. aureus or 3.65 3 108 CFU/mouse
of isogenic a-toxin-deficient Hla– S. aureus and monitored for the signs of moribund condition for up to 72 hr.
(I) Body temperature for control noninfected mice and S. aureus-infected mice at 2, 6, and 16 hr postinfection is shown (median and individual values; NT,
not tested).
See also Figure S3.
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Phospholipids, eATP Release, and PLSCR1 Subcellular
Localization
Since PLSCR1 has been implicated in nonspecific bidirectional
translocation (scrambling) of membrane phospholipids (Stout
et al., 1997), we evaluated whether IFNa pretreatment alters
translocation of membrane phospholipids after a-toxin expo-Cell Hsure. Binding of annexin V, which indicated exposure of
phosphatidylserine on cell surface, significantly increased after
treatment with a-toxin in medium- but not in IFNa-pretreated
cells (Figure 5A). In addition, we used FM1-43, a fluorescent
reporter for plasma membrane phospholipid scrambling (Zwei-
fach, 2000). Exposure of medium and IFNa-pretreated cells to
a-toxin showed significantly increased binding of FM1-43, albeitost & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier Inc. 75
Figure 5. Effects of IFNa and a-Toxin on Scrambling of Membrane Phospholipids, eATP Release and PLSCR1 Subcellular Localization
Translocation of membrane phospholipids was analyzed in A549 cells pretreated with medium or IFNa for 24 hr and treated with 2.5 mg/ml a-toxin.
(A) Binding of Cy5.5-labeled annexin V to phosphatidylserine on cell surface was measured by LICOR Odyssey imaging system. Representative images and
normalized integrated fluorescence intensity at 2 hr after a-toxin are shown. The data are mean ± SD of triplicate cultures and are representative of three
independent experiments.
(B) Uptake of lipophilic fluorescent dye FM1-43 at 2 hr after a-toxin. Normalized fluorescence intensity is shown. The data are mean ± SD of triplicate cultures and
are representative of three independent experiments. A549 cells stably expressing PLSCR1-specific or nonsilencing (NS) shRNA were pretreated with IFNa and
exposed to 2.5 mg/ml a-toxin.
(C) Kinetics of eATP release. The curves represent normalized mean luminescence intensity of quadruplicate cultures.
(D) Concentration of eATP in the culture medium at 30 min after a-toxin (mean ± SD of quadruplicate cultures). The data are representative of three independent
experiments.
(E) Subcellular protein fractions were obtained from A549 cells pretreatedwith medium or IFNa and treated with a-toxin for the indicated time points and analyzed
for expression of PLSCR1 by immunoblotting. Representative immunoblots and normalized densitometry values from two independent experiments are shown.
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ure 5B). Thus, two independent assays showed that increased
expression of PLSCR1 in IFNa-pretreated cells does not corre-
late with translocation of membrane phospholipids after a-toxin
exposure.
To define how PLSCR1 mediates IFNa-induced protection
from a-toxin, we measured eATP release from A549 cells stably
expressing NS or PLSCR1-specific shRNA. In the absence of
IFNa pretreatment, A549 cells stably expressing NS or
PLSCR1-specific shRNA released similarly high levels of eATP
in response to a-toxin (Figures 5C and 5D). Pretreatment with
IFNa significantly reduced eATP release from the cells express-
ing NS shRNA. However, the response to IFNa pretreatment
was attenuated in the cells expressing PLSCR1-specific shRNA.
These data indicated that IFNa-induced PLSCR1 is necessary
for reduction of eATP release after exposure to a-toxin.
Nuclear translocation of PLSCR1 augments transcriptional
responses to type IFNs and G-CSF (Chen et al., 2011; Dong
et al., 2004). To provide further insight into how IFNa-induced
PLSCR1may protect cells from a-toxin, we analyzed subcellular
protein fractions for the presence of PLSCR1 after treatment
with IFNa and/or a-toxin. After IFNa pretreatment, PLSCR1
accumulated in the nuclear, membrane, and cytoskeleton-
associated fractions (Figure 5E). Treatment with a-toxin had
no effect on the amounts of PLSCR1 in the nuclear fractions (Fig-
ure 5E, top). After exposure to a-toxin, membrane-associated
PLSCR1 decreased in medium-pretreated cells, but increased
in IFNa-pretreated cells (Figure 5E, middle). Remarkably, treat-
ment with a-toxin led to sustained increases of PLSCR1 in the
cytoskeleton-associated fractions, both in the medium- and
IFNa-pretreated cells (Figure 5E, bottom). Moreover, immunoflu-
orescence analyses of PLSCR1 after IFNa pretreatment and
exposure to a-toxin showed colocalization of PLSCR1 and
F-actin (detected by phalloidin staining) in a subset of cells (Fig-
ure 5F and Figure S4). In summary, these results indicated that
exposure to a-toxin does not lead to nuclear translocation of
PLSCR1, but results in accumulation of PLSCR1 in the cytoskel-
eton-associated protein fractions, at least in some cells.
Using wild-type PLSCR1 and PLSCR1 with mutations in pal-
mitoylation sites or in nuclear localization signal (Wiedmer
et al., 2003; Chen et al., 2005), we analyzed whether overexpres-
sion of PLSCR1 may be sufficient to protect cells from a-toxin.
Overexpressed wild-type PLSCR1 localized primarily to the
nucleus, albeit some diffuse extranuclear expression of PLSCR1
was also observed (Figure S4). Similar subcellular localization
was observed for PLSCR1 with the mutations in the palmitoyla-
tion sites (184AAAPAA189, further referred as C-A mutant, Fig-
ure S4). The mutations in the nuclear localization signals
(K258A, K261A/H263A, further referred as K-Amutant) excluded
PLSCR1 from the nucleus (Figure S4). To evaluate the effects of(F) Immunofluorescence staining for PLSCR1 and phalloidin staining for F
30 min. A representative photomicrograph from two independent experiments
plasmids expressing GFP alone, wild-type PLSCR1 or nuclear localization mu
a-toxin.
(G) Release of eATP was measured at 30 min after a-toxin.
(H) Total cellular ATP wasmeasured at 16 hr after a-toxin and normalized to total c
cultures and are representative of two independent experiments.
See also Figure S4.
Cell Hthese expression constructs on responses to a-toxin, we sorted
transiently transfected cells by flow cytometry using the GFP
marker in the bicistronic pMIG-IRES-GFP vector. Although we
easily obtained more than 98% GFP+ populations of cells with
>94% postsort cell viability for cells expressing wild-type and
K-A mutant PLSCR1, we were not able to obtain sufficient
numbers of viable A549 cells transfected with the C-A mutant
PLSCR1. We also could not produce stably transfected A549
cells expressing this construct, which suggested that expression
of palmitoylation-deficient PLSCR1 in A549 cells may result in
toxicity. When we treated the sorted A549 cells with a-toxin, we
found that wild-type or K-A mutant PLSCR1 decreased release
of eATP at 30 min after a-toxin (Figure 5G). Moreover, A549 cells
overexpressing PLSCR1 or K-A PLSCR1 retained more ATP at
16 hr after a-toxin treatment (Figure 5H). Thus, regardless of
PLSCR1 nuclear localization, its overexpression is sufficient to
replicate the effects of IFNa on cell responses to a-toxin.
DISCUSSION
Our results show that exposure of human lung epithelial cells to
a-toxin leads to eATP release into extracellular space. Impor-
tantly, IFNa protects human lung epithelial cells from a-toxin
by reducing eATP release and allowing cells to maintain suffi-
cient levels of intracellular ATP. To identify pathways and IFN-
regulated genes involved in protection from a-toxin, we used
a screening assay and bioinformatics analyses. As a result, we
found that protein palmitoylation and induction of PLSCR1 are
necessary to reduce ATP depletion and cell death.
Using PLSCR1-specific RNA interference, we demonstrated
that induction of PLSCR1 is necessary for IFNa-induced protec-
tion from a-toxin. Our experiment with PLSCR1/ mice also
suggested that PLSCR1 is involved in host responses to a-toxin
in vivo. Importantly, PLSCR1 deficiency increased susceptibility
of mice to the pulmonary infection with a-toxin-producing
S. aureus. Thus, our findings reveal a function for PLSCR1 in
protection of host cells from a bacterial pore-forming toxin.
Palmitoylation of PLSCR1 is required for localization of
PLSCR1 to lipid rafts in the plasma membrane (Wiedmer et al.,
2003), where it may contribute to nonselective translocation of
phospholipids across the plasma membrane bilayer (Stout
et al., 1997), albeit the latter notion is disputable (Bevers and
Williamson, 2010). Nonpalmitoylated PLSCR1 amplifies tran-
scriptional responses to IFNa and G-CSF in the nucleus (Chen
et al., 2011; Dong et al., 2004). As we observed increased levels
of PLSCR1 in several subcellular compartments after IFNa
pretreatment, it is possible that PLSCR1 contributes to induction
of other IFN-regulated genes mediating protection from a-toxin.
Due to potential toxicity of palmitoylation mutant PLSCR1 in
A549 cells, we cannot completely rule out the possibility that-Actin in A549 cells after IFNa pretreatment and a-toxin exposure for
is shown. The scale bar represents 20 mm. A549 cells were transfected with
tant K-A PLSCR1, sorted for GFP coexpression, replated, and treated with
ellular ATP without a-toxin treatment. The data are mean ± SD of quadruplicate
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tion from a-toxin. However, overexpression of K-A mutant
PLSCR1, which is essentially excluded from the nucleus, was
sufficient to replicate some of the IFNa effects, such as eATP
release and retaining intracellular ATP. Thus, extranuclear
PLSCR1 has cytoprotective functions.
In addition, we observed that exposure of cells to a-toxin led
to colocalization of PLSCR1 with endocytosed a-toxin and
polymerized F-actin, and accumulation of PLSCR1 in the
cytoskeleton-associated protein fractions. Binding of a-toxin
to ADAM10 on lung epithelial cells impairs actin cytoskeleton
(Wilke and Bubeck Wardenburg, 2010), whereas disruption of
actin cytoskeleton by cytochalasin D prevents repair of a-toxin
pores in fibroblasts and sensitizes them to a-toxin (Valeva
et al., 2000). Furthermore, endocytosis, ‘‘detoxification,’’ and
exocytosis of a-toxin are important mechanisms of cellular resis-
tance to a-toxin (Husmann et al., 2009). We did not observe
coimmunoprecipitation of PLSCR1 with a-toxin, ADAM10, or
F-actin (data not shown). Thus, PLSCR1 is likely to protect cells
from a-toxin without disruption of a-toxin interaction with
ADAM10. Our findings place PLSCR1 in a highly relevant sub-
cellular compartments and call for further characterization of
PLSCR1 functions and potential interacting molecular partners
in this context.
We also showed that a-toxin triggers rapid, robust, and sus-
tained release of eATP, which was partially inhibited by IFNa
pretreatment in a PLSCR1-dependent manner. Extracellular
nucleotides regulate lung barrier functions, survival activation,
and recruitment of epithelial cells and leukocytes (Eckle et al.,
2009; Junger, 2011), and we found that oxidized ATP, a nonse-
lective antagonist of P2 receptors, protected cells and mice
against a-toxin. Therefore, further studies targeting release of
extracellular nucleotides and/or purinergic receptor signaling
should help determine the roles of extracellular nucleotides in
pathogenesis of staphylococcal infections.
In conclusion, our study describes an innate immune program
downstream of type I IFNs that induces PLSCR1 and mediates
protection of host cells from death caused by a bacterial pore-
forming toxin. This potentially beneficial process is apparently
distinct from previously described deleterious effects of type I
IFNs during bacterial infections (Carrero et al., 2004; Martin
et al., 2009). Additional studies will be necessary to investigate
the role of PLSCR1 during in vivo infections with live S. aureus.
EXPERIMENTAL PROCEDURES
Reagents
We purchased staphylococcal a-toxin (specific activity 30,000 hemolytic units
per mg) from List Biological Laboratories, human recombinant IFNa (specific
activity at least 2 3 108 U/mg) from PBL InterferonSource, calcein-AM and
ethidium homodimer (EthD-1) from Invitrogen, SB203580, UO126, AG1478,
LY294002, actinomycin D, and cycloheximide from EMD Biochemicals, and
cerulenin and 2-bromo-palmitate from Sigma.
Cell Cultures
We purchased A549 cells from ATCC and SAECs (derived from three separate
donors) from ATCC and Lonza and cultured them according to the manufac-
turers’ recommendations. For functional assays, we seeded SAECs or A549
cells at 10,000 cells/well in 96-well plates, pretreated the cells with human re-
combinant IFNa (1000 U/ml) for 24 hr, changed the culturemedium, and added
diluted a-toxin or conditioned medium from S. aureus cultures. To obtain78 Cell Host & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier Iconditioned medium from S. aureus cultures, we inoculated single colonies
into 10 ml of tryptic soy broth (TSB), cultured the bacteria for 24 hr, pelleted
them by centrifugation at 3000 g for 10 min, and sterilized the supernatants
with 0.22 mm filters (Millipore). Hla+ strain of S. aureus (DU5617) and its
isogenicHla–mutant DU5618 were a generous gift from Timothy Foster (Trinity
College, Dublin) (O’Reilly et al., 1986).
Assessment of Cell Death
To measure a-toxin-induced cell death in cultured cells, we stained live cells
with 1 mMcalcein AM and dead cells with 8 mMEthD-1 (Invitrogen). We omitted
calcein AM staining in experiments with shRNA since fluorescence of GFP
expressed from the vector clearly marked live cells. We acquired images
from random fields in at least four individual wells per group using inverted
fluorescent microscope DMIRB (Leica) with 203/0.40 objective and
DC350FX camera (Leica) ImagePro software, and we manually counted live
(green) and dead (red) cells. In some experiments, we measured death of
A549 cells harvested by trypsinization using exclusion of trypan blue and
TC10 automated cell counter (Bio-Rad) or using exclusion of 7-amino-actino-
mycin D (BD Biosciences) and flow cytometry.
Assessment of Intracellular ATP
To measure cellular ATP after a-toxin treatment, we added equal volume of
CellTiter Glo reagent (Promega) to the wells with cells in the medium and, after
10 min incubation at room temperature with shaking, transferred the lysates to
opaque LumiTrac plates (Greiner) and measured luminescence intensity using
a Synergy HT plate reader (BioTek). We adjusted the sensitivity of the detector
every time to remain in the linear mode. We normalized luminescence intensity
from IFNa- or a-toxin-treated cells to the luminescence intensity from cells
treated with medium alone.
Screening Assay and Bioinfomatics Analyses
After pretreatment of A549 cells with IFNa for 24 hr, we pretreated cells with
a panel of 20 commercially available inhibitors of signaling pathways for
30 min and treated cells with a-toxin (0.5 and 2.5 mg/ml). We used carrier solu-
tions (DMSO or ethanol) or negative control chemicals (i.e., zFA-FMK for
zVAD-FMK) for control groups. After exposure of cells to a-toxin for 16 hr,
we measured relative intracellular ATP as described above. To determine
the interaction between the inhibitors and IFNa-pretreatment, we compared
the remaining relative ATP levels after a-toxin treatment with or without the
inhibitor (normalized to cells incubated in complete medium with carrier solu-
tion but without a-toxin) using two-way ANOVA assay.
To identify candidate genes involved in IFN-induced protection from a-toxin,
we compiled the list of palmitoylation-associated human genes using pub-
lished studies (Yang et al., 2010) and gene ontology records in GenBank
(http://www.ncbi.nlm.nih.gov/genbank/). We found the overlap between this
list and the list of IFN-regulated genes expressed in A549 cells (Sanda et al.,
2006) using Biovenn web application (Hulsen et al., 2008).
Measurement of eATP Release
For detection of eATP release in real time, we diluted luciferin/luciferase
reagent from the ATP Bioluminescence Assay Kit CLS II (Roche) in phenol
red free and serum free DMEM (Invitrogen) and added it directly to SAEC
and A549 cell cultures for 5 min. After this equilibration period, we added
a-toxin or diluted conditioned medium from S. aureus cultures and measured
luminescence intensity every min for up to 60 min at 37C.
To measure eATP concentrations, we cultured cells with a-toxin in phenol
red free and serum free DMEM for the indicated time points and collected
conditioned medium with a multichannel pipet into U-bottom microtiter plates
kept on ice. After a 5min centrifugation at 300 g at 4C, we transferred cell-free
supernatants (25 ml) into plates prefilled with 25 ml/well CellTiter Glo reagent
(Promega) and measured luminescence intensity using a Synergy HT plate
reader after 10 min incubation at room temperature with shaking. To generate
the standard curves, we diluted ATP standards (Teknova) fresh every time in
the culture medium.
Assessment of Translocation of Membrane Phospholipids
We treated A549 cells plated in clear bottom 96-well plates with IFNa and
a-toxin as indicated above. At the indicated time points, we stained the cellsnc.
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and scanned the plates with Odyssey imaging system (LICOR) using its
700 nm channel. Alternatively, we added lipophilic dye FM1-43 (5 mg/ml) to
the cells after treatment with IFNa and a-toxin and measured its uptake after
5min incubationwith the Synergy plate reader using 508/20 nm excitation filter
and 640/40 nm emission filter.
Knockdown and Overexpression of PLSCR1 in A549 Cells
PLSCR1-specific shRNA and control nonsilencing shRNA subcloned into
pLMP-IRES-GFP vector were a generous gift from Peter Sims and Therese
Wiedmer (University of Rochester Medical Center). The PLSCR1-specific
shRNA targets positions 1231–1252 within PLSCR1 messenger RNA
(mRNA) (GenBank accession number NM_021105.2). The stem of the hairpin
in the NS shRNA shows no homology to known human mRNAs. We stably
transfected A549 cells with the shRNA-expressing vectors with Lipofectamine
and maintained established clones (four for each shRNA construct) in the
presence of puromycin. Palmitoylation C-A mutant and nuclear localization
K-A mutant (Wiedmer et al., 2003; Chen et al., 2005) were subcloned into
pMIG-IRES-GFP vectors and obtained fromPeter Sims and ThereseWiedmer.
We overexpressed mutant PLSCR1 and wild-type PLSCR1 by transiently
transfecting A549 cells with FuGENE HD (Roche Applied Science) and sorting
GFP+ cells using Sony-iCyt Reflection sorter at the Cell Sorter Core Facility
(Yale University School of Medicine).
Subcellular Fractionation and Immunoblotting
For total protein lysates, we scraped cells from 100 mm dishes in lysis buffer
containing 1% Igepal (Sigma) and cleared cell lysates by centrifugation at
14,000 g for 10 min at 4C. We isolated subcellular protein fractions using
Subcellular fractionation kit from Pierce. For immunoblotting, we separated
proteins in 4%–15% precast gradient gels (Biorad), transferred onto nitrocel-
lulose membranes, blocked, and incubated with primary and near infrared
fluorescently labeled secondary antibodies using reagents and protocols
from LICOR. We scanned and analyzed immunoblots using Odyssey imaging
system (LICOR).
Immunofluorescence
We seeded cells into 8-well LabTek chamber slides and treated them with
IFNa and/or a-toxin for the indicated times. We washed cells with warm
PBS containing calcium and magnesium, fixed with 4% paraformaldehyde,
blocked with 10% FBS or normal goat serum, permeabilized with 0.1% Triton
X-100 and stained with the indicated antibodies for PLSCR1 or a-toxin. We
used Alexa Fluor-488-conjugated phalloidin to visualize polymerized F-Actin
and DAPI for nuclear counterstaining. We acquired images using DMIRB
microscope with 203/0.75 objective, DC350FX camera (Leica) and ImagePro
software or Nikon Eclipse 80i epifluorescence microscope with Retiga 2000R
camera and NIS Elements software.
In Vivo Experiments
All studies with animals were carried out following a protocol approved by Yale
University IACUC. We purchased C57BL/6 mice from the animal production
facility of National Cancer Institute and PLSCR1+/ mice (F1 hybrids of
C57BL/6 and 129 strains) from Texas Institute of Genomic Medicine (Zhou
et al., 2002). We crossed PLSCR1+/ mice to obtain F2 littermate wild-type,
heterozygous, and homozygous PLSCR1-knockout mice. Since wild-type
and heterozygous mice showed no apparent difference in PLSCR1 expression
levels (data not shown), we used sex-matched heterozygous mice as controls
for knockouts. To evaluate the responses of mice to inhaled a-toxin, we anes-
thetized mice with isoflurane and administered 50 ml of sterile PBS containing
sublethal doses of a-toxin (50 mg/kg body weight) via intranasal route. Where
indicated we mixed oxidized ATP (0.335 mmol/mouse) or equivalent volume of
PBS with a-toxin immediately prior to administration to mice. We measured
body temperature prior to a-toxin and at the indicated time points with an
infrared thermometer (Exergen). We euthanized all mice with CO2 at the end
of the experiments.
For infection with live S. aureus, we diluted overnight cultures of S. aureus
1:100 in 50 ml TSB, subcultured for 2 hr, washed twice with sterile PBS, and
resuspended the pellets in 1.5 ml of sterile PBS. We administered 50 ml of
the bacterial suspension to isoflurane-anesthetized mice via intranasal routeCell Hand determined the actual dose of live S. aureus by plating serial dilutions on
TSB agar plates. We monitored mice at regular intervals for up to 72 hr for the
following signs of moribund condition: sustained hypothermia (body tempera-
ture <28C for more than 1 hr as measured by the infrared thermometer), leth-
argy, dehydration, change in the color of mucous membranes, labored
breathing. We determined that mice showing more than three of the indicated
signs were moribund and euthanized them promptly with CO2. The time of
developing this moribund condition was recorded to plot the survival curves.
Statistical Analyses
In experiments involving more than two experimental groups, we determined
whether the difference between the groups was statistically significant using
one-way analysis of variance test and Bonferroni posttest. Otherwise, we
used two-tailed student’s t test. We analyzed the differences in body temper-
ature between the groups of infected mice using Kruskal-Wallis nonpara-
metric test followed by Dunn’s posttest for all groups. We analyzed the
survival curves using the log-rank (Mantel-Cox) test. To perform all calcula-
tions we used GraphPad Prism software, version 4 (GraphPad Software,
San Diego, CA).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.chom.2011.12.004.
ACKNOWLEDGMENTS
This work was funded by National Institutes of Health grant 5R21AI79322 (T.Y.)
and the Pilot Project from the Yale Liver Center (DK P30-34989). The authors
are grateful to Peter Sims and Therese Wiedmer (University of Rochester
Medical Center) for providing PLSCR1-specific and control shRNA constructs
and PLSCR1 overexpression vectors, which were instrumental for this study.
We also thank Martha Monick and Gary Hunninghake (The University of
Iowa) for their inspiration and support at the initial stages of this work.We thank
Daniel Goldstein (Yale University School of Medicine) for critical reading of the
manuscript and very helpful suggestions. Finally, we are very grateful to Jeffrey
Bender (Yale University School of Medicine), whose generous support and
encouragement were crucial for completion of this work.
Received: August 19, 2011
Revised: November 10, 2011
Accepted: December 19, 2011
Published: January 18, 2012
REFERENCES
Bartlett, A.H., Foster, T.J., Hayashida, A., and Park, P.W. (2008). Alpha-toxin
facilitates the generation of CXC chemokine gradients and stimulates neutro-
phil homing in Staphylococcus aureus pneumonia. J. Infect. Dis. 198, 1529–
1535.
Bevers, E.M., and Williamson, P.L. (2010). Phospholipid scramblase: an
update. FEBS Lett. 584, 2724–2730.
Bhakdi, S., and Tranum-Jensen, J. (1991). Alpha-toxin of Staphylococcus
aureus. Microbiol. Rev. 55, 733–751.
Bubeck Wardenburg, J., and Schneewind, O. (2008). Vaccine protection
against Staphylococcus aureus pneumonia. J. Exp. Med. 205, 287–294.
Carrero, J.A., Calderon, B., and Unanue, E.R. (2004). Type I interferon sensi-
tizes lymphocytes to apoptosis and reduces resistance to Listeria infection.
J. Exp. Med. 200, 535–540.
Chawla-Sarkar, M., Lindner, D.J., Liu, Y.F., Williams, B.R., Sen, G.C.,
Silverman, R.H., and Borden, E.C. (2003). Apoptosis and interferons: role of
interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249.
Chen, M.H., Ben-Efraim, I., Mitrousis, G., Walker-Kopp, N., Sims, P.J., and
Cingolani, G. (2005). Phospholipid scramblase 1 contains a nonclassical
nuclear localization signal with unique binding site in importin alpha. J. Biol.
Chem. 280, 10599–10606.ost & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier Inc. 79
Cell Host & Microbe
Scramblase 1 and Staphylococcal Alpha-ToxinChen, C.W., Sowden, M., Zhao, Q., Wiedmer, T., and Sims, P.J. (2011).
Nuclear phospholipid scramblase 1 prolongs the mitotic expansion of granu-
locyte precursors during G-CSF-induced granulopoiesis. J. Leukoc. Biol. 90,
221–233.
Craven, R.R., Gao, X., Allen, I.C., Gris, D., BubeckWardenburg, J., McElvania-
Tekippe, E., Ting, J.P., and Duncan, J.A. (2009). Staphylococcus aureus
alpha-hemolysin activates the NLRP3-inflammasome in human and mouse
monocytic cells. PLoS ONE 4, e7446.
De Vuyst, E., Decrock, E., De Bock, M., Yamasaki, H., Naus, C.C., Evans,
W.H., and Leybaert, L. (2007). Connexin hemichannels and gap junction
channels are differentially influenced by lipopolysaccharide and basic fibro-
blast growth factor. Mol. Biol. Cell 18, 34–46.
Dong, B., Zhou, Q., Zhao, J., Zhou, A., Harty, R.N., Bose, S., Banerjee, A., Slee,
R., Guenther, J., Williams, B.R., et al. (2004). Phospholipid scramblase 1
potentiates the antiviral activity of interferon. J. Virol. 78, 8983–8993.
Eckle, T., Koeppen, M., and Eltzschig, H.K. (2009). Role of extracellular aden-
osine in acute lung injury. Physiology (Bethesda) 24, 298–306.
Gurcel, L., Abrami, L., Girardin, S., Tschopp, J., and van der Goot, F.G. (2006).
Caspase-1 activation of lipid metabolic pathways in response to bacterial
pore-forming toxins promotes cell survival. Cell 126, 1135–1145.
Hulsen, T., de Vlieg, J., and Alkema, W. (2008). BioVenn - a web application for
the comparison and visualization of biological lists using area-proportional
Venn diagrams. BMC Genomics 9, 488.
Husmann, M., Dersch, K., Bobkiewicz, W., Beckmann, E., Veerachato, G., and
Bhakdi, S. (2006). Differential role of p38 mitogen activated protein kinase
for cellular recovery from attack by pore-forming S. aureus alpha-toxin or
streptolysin O. Biochem. Biophys. Res. Commun. 344, 1128–1134.
Husmann, M., Beckmann, E., Boller, K., Kloft, N., Tenzer, S., Bobkiewicz, W.,
Neukirch, C., Bayley, H., and Bhakdi, S. (2009). Elimination of a bacterial
pore-forming toxin by sequential endocytosis and exocytosis. FEBS Lett.
583, 337–344.
Idone, V., Tam, C., and Andrews, N.W. (2008). Two-way traffic on the road to
plasma membrane repair. Trends Cell Biol. 18, 552–559.
Inoshima, I., Inoshima, N., Wilke, G.A., Powers, M.E., Frank, K.M., Wang, Y.,
and Bubeck Wardenburg, J. (2011). A Staphylococcus aureus pore-forming
toxin subverts the activity of ADAM10 to cause lethal infection in mice.
Nat. Med. 17, 1310–1314.
Junger, W.G. (2011). Immune cell regulation by autocrine purinergic signalling.
Nat. Rev. Immunol. 11, 201–212.
Kallen, A.J., Mu, Y., Bulens, S., Reingold, A., Petit, S., Gershman, K., Ray,
S.M., Harrison, L.H., Lynfield, R., Dumyati, G., et al; Active Bacterial Core
surveillance (ABCs) MRSA Investigators of the Emerging Infections Program.
(2010). Health care-associated invasive MRSA infections, 2005-2008. JAMA
304, 641–648.
Kennedy, A.D., Bubeck Wardenburg, J., Gardner, D.J., Long, D., Whitney,
A.R., Braughton, K.R., Schneewind, O., and DeLeo, F.R. (2010). Targeting of
alpha-hemolysin by active or passive immunization decreases severity of
USA300 skin infection in a mouse model. J. Infect. Dis. 202, 1050–1058.
Martin, F.J., Gomez, M.I., Wetzel, D.M., Memmi, G., O’Seaghdha, M., Soong,
G., Schindler, C., and Prince, A. (2009). Staphylococcus aureus activates type I
IFN signaling in mice and humans through the Xr repeated sequences of
protein A. J. Clin. Invest. 119, 1931–1939.
McCormick, C.C., Caballero, A.R., Balzli, C.L., Tang, A., and O’Callaghan, R.J.
(2009). Chemical inhibition of alpha-toxin, a key corneal virulence factor of
Staphylococcus aureus. Invest. Ophthalmol. Vis. Sci. 50, 2848–2854.
Menzies, B.E., and Kernodle, D.S. (1996). Passive immunization with anti-
serum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is
protective in a murine model. Infect. Immun. 64, 1839–1841.
O’Reilly, M., de Azavedo, J.C., Kennedy, S., and Foster, T.J. (1986).
Inactivation of the alpha-haemolysin gene of Staphylococcus aureus 8325-4
by site-directed mutagenesis and studies on the expression of its haemoly-
sins. Microb. Pathog. 1, 125–138.
Pre´vost, G.,Mourey, L., Colin, D.A., andMenestrina, G. (2001). Staphylococcal
pore-forming toxins. Curr. Top. Microbiol. Immunol. 257, 53–83.80 Cell Host & Microbe 11, 70–80, January 19, 2012 ª2012 Elsevier IRagle, B.E., and Bubeck Wardenburg, J. (2009). Anti-alpha-hemolysin
monoclonal antibodies mediate protection against Staphylococcus aureus
pneumonia. Infect. Immun. 77, 2712–2718.
Ratner, A.J., Hippe, K.R., Aguilar, J.L., Bender, M.H., Nelson, A.L., andWeiser,
J.N. (2006). Epithelial cells are sensitive detectors of bacterial pore-forming
toxins. J. Biol. Chem. 281, 12994–12998.
Robertson, J., Lang, S., Lambert, P.A., and Martin, P.E. (2010). Peptidoglycan
derived from Staphylococcus epidermidis induces Connexin43 hemichannel
activity with consequences on the innate immune response in endothelial cells.
Biochem. J. 432, 133–143.
Rose, F., Dahlem, G., Guthmann, B., Grimminger, F., Maus, U., Ha¨nze, J.,
Duemmer, N., Grandel, U., Seeger, W., and Ghofrani, H.A. (2002). Mediator
generation and signaling events in alveolar epithelial cells attacked by
S. aureus alpha-toxin. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L207–L214.
Sanda, C., Weitzel, P., Tsukahara, T., Schaley, J., Edenberg, H.J., Stephens,
M.A., McClintick, J.N., Blatt, L.M., Li, L., Brodsky, L., and Taylor, M.W.
(2006). Differential gene induction by type I and type II interferons and their
combination. J. Interferon Cytokine Res. 26, 462–472.
Schreiber, M.P., Chan, C.M., and Shorr, A.F. (2011). Bacteremia in
Staphylococcus aureus pneumonia: outcomes and epidemiology. J. Crit.
Care 26, 395–401.
Seminario-Vidal, L., Lazarowski, E.R., and Okada, S.F. (2009). Assessment of
extracellular ATP concentrations. Methods Mol. Biol. 574, 25–36.
Skals, M., Jorgensen, N.R., Leipziger, J., and Praetorius, H.A. (2009). Alpha-
hemolysin from Escherichia coli uses endogenous amplification through
P2X receptor activation to induce hemolysis. Proc. Natl. Acad. Sci. USA 106,
4030–4035.
Stout, J.G., Basse´, F., Luhm, R.A., Weiss, H.J., Wiedmer, T., and Sims, P.J.
(1997). Scott syndrome erythrocytes contain a membrane protein capable of
mediating Ca2+-dependent transbilayer migration of membrane phospho-
lipids. J. Clin. Invest. 99, 2232–2238.
Valeva, A., Walev, I., Pinkernell, M., Walker, B., Bayley, H., Palmer, M., and
Bhakdi, S. (1997). Transmembrane beta-barrel of staphylococcal alpha-toxin
forms in sensitive but not in resistant cells. Proc. Natl. Acad. Sci. USA 94,
11607–11611.
Valeva, A., Walev, I., Gerber, A., Klein, J., Palmer, M., and Bhakdi, S. (2000).
Staphylococcal alpha-toxin: repair of a calcium-impermeable pore in the
target cell membrane. Mol. Microbiol. 36, 467–476.
Valeva, A., Hellmann, N., Walev, I., Strand, D., Plate, M., Boukhallouk, F.,
Brack, A., Hanada, K., Decker, H., and Bhakdi, S. (2006). Evidence that
clustered phosphocholine head groups serve as sites for binding and
assembly of an oligomeric protein pore. J. Biol. Chem. 281, 26014–26021.
Wiedmer, T., Zhao, J., Nanjundan, M., and Sims, P.J. (2003). Palmitoylation of
phospholipid scramblase 1 controls its distribution between nucleus and
plasma membrane. Biochemistry 42, 1227–1233.
Wilke, G.A., and Bubeck Wardenburg, J. (2010). Role of a disintegrin and met-
alloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular
injury. Proc. Natl. Acad. Sci. USA 107, 13473–13478.
Yang, W., Di Vizio, D., Kirchner, M., Steen, H., and Freeman, M.R. (2010).
Proteome scale characterization of human S-acylated proteins in lipid raft-
enriched and non-raft membranes. Mol. Cell. Proteomics 9, 54–70.
Yarovinsky, T.O.,Monick,M.M., Husmann,M., andHunninghake, G.W. (2008).
Interferons increase cell resistance to Staphylococcal alpha-toxin. Infect.
Immun. 76, 571–577.
Zhou, Q., Zhao, J., Al-Zoghaibi, F., Zhou, A., Wiedmer, T., Silverman, R.H., and
Sims, P.J. (2000). Transcriptional control of the human plasma membrane
phospholipid scramblase 1 gene is mediated by interferon-alpha. Blood 95,
2593–2599.
Zhou, Q., Zhao, J., Wiedmer, T., and Sims, P.J. (2002). Normal hemostasis but
defective hematopoietic response to growth factors in mice deficient in phos-
pholipid scramblase 1. Blood 99, 4030–4038.
Zweifach, A. (2000). FM1-43 reports plasma membrane phospholipid scram-
bling in T-lymphocytes. Biochem. J. 349, 255–260.nc.
